Cardiovascular toxicity risk assessment of tyrosine kinase inhibitors: a pharmacovigilance study using the VigiBase database
Yusuke Igawa, Hirofumi Hamano, Satoru Esumi, Tatsuaki Takeda, Makoto Kajizono, Ryo Kikuoka, Ikuya Kimura, Yoshito Zamami · 2024
Read Cardiovascular toxicity risk assessment of tyrosine kinase inhibitors: a pharmacovigilance study using the VigiBase database by Yusuke Igawa, Hirofumi Hamano, Satoru Esumi, Tatsuaki Takeda, Makoto Kajizono, Ryo Kikuoka, Ikuya Kimura, Yoshito Zamami (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11646760.txt.
Description
Yusuke Igawa and colleagues assess heart toxicity risks of targeted cancer drugs using the World Health Organization's global side-effect database. Their 2024 pharmacovigilance study mines tens of millions of suspected drug reaction reports filed through twenty twenty-two.
The drugs block growth signals in many cancers but differ in targets, handling, and side effects, including heart problems that threaten survivors' prognosis. Reports involving approved drugs of this class were analysed by age and sex. Heart impairment was defined by twenty-one standard coded terms. Statistical disproportionality analysis flagged which drugs showed unusually strong heart toxicity signals. Significant cardiovascular signals emerged for several agents in the enormous dataset, detailed drug by drug in the full report.
Catalog record
| CREATOR | Yusuke Igawa, Hirofumi Hamano, Satoru Esumi, Tatsuaki Takeda, Makoto Kajizono, Ryo Kikuoka, Ikuya Kimura, Yoshito Zamami |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |